Cargando…
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy
AIMS: The goal of the study was to evaluate the efficacy of epalrestat, an aldose reductase inhibitor, on diabetic retinopathy and diabetic nephropathy, based on analysis of the results of the Aldose Reductase Inhibitor–Diabetes Complications Trial, a 3-year multicentre comparative clinical trial of...
Autores principales: | Hotta, N, Kawamori, R, Fukuda, M, Shigeta, Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533175/ https://www.ncbi.nlm.nih.gov/pubmed/22507139 http://dx.doi.org/10.1111/j.1464-5491.2012.03684.x |
Ejemplares similares
-
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective
por: Sharma, S. R., et al.
Publicado: (2008) -
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat
por: Hotta, N, et al.
Publicado: (2008) -
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
por: Iyer, Sangeetha, et al.
Publicado: (2019) -
Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats
por: Yang, Bai-Bing, et al.
Publicado: (2018) -
Correction: Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats
por: Yang, Bai-Bing, et al.
Publicado: (2019)